Skip Navigation

European Journal of Heart Failure 2003 5(2):187-193; doi:10.1016/S1388-9842(02)00202-7
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pont, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pont, L. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in general practice

Lisa G. Ponta,*, Wiek H. van Gilsta, Dirk J.A. Lokb, Hans J.A. Kragtenc, Flora M. Haaijer-Ruskampa and on behalf of the Dutch Working Group on Heart Failure

a Department of Clinical Pharmacology, University of Groningen Ant. Deusinglaan 1, 9713 AV, Groningen, The Netherlands
b Department of Cardiology, Deventer Hospital Deventer, The Netherlands
c Department of Cardiology, Atrium Medical Centre Heerlen, The Netherlands

* Corresponding author. Tel.: +61-2-96994499; fax: +61-2-96995155 E-mail address: l.pont{at}nps.org.au


   Abstract

Aims: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is sub-optimal. Traditionally, assessment of drug use in heart failure has focused on the use of individual agents irrespective of CHF severity. This study investigates drug use for CHF patients in general practice with respect to the available evidence, incorporating both disease severity and the use of combination drug regimes.

Methods and results: A cross-sectional survey of 769 Dutch CHF patients was performed as part of IMPROVEMENT of HF study. For each New York Heart Association severity classification the minimum treatment appropriate for the heart failure severity according to the scientific evidence available at the time of the study (1999) was defined. The proportion of patients treated with each drug increased with increasing severity, with the exception of the β-blockers. Patients with less severe heart failure were approximately four to eight times more likely to receive evidence-based treatment than those with more severe heart failure.

Discussion: To assess pharmacological treatment of heart failure, in relation to the available evidence, it is important to take severity into account. While the number of drugs prescribed increased with increasing severity, the use of evidence-based regimes was lower in patients with more severe heart failure.

Key Words: Heart failure • General practice • Pharmacotherapy • Evidence-based practice

Received March 18, 2002; Revised July 23, 2002; Accepted October 3, 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
H. B. Sturm, F. M. Haaijer-Ruskamp, N. J. Veeger, C. P. Balje-Volkers, K. Swedberg, and W. H. van Gilst
The relevance of comorbidities for heart failure treatment in primary care: A European survey
Eur J Heart Fail, January 1, 2006; 8(1): 31 - 37.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
T. Jaarsma, F. M. Haaijer-Ruskamp, H. Sturm, and D. J. Van Veldhuisen
Management of heart failure in The Netherlands
Eur J Heart Fail, March 16, 2005; 7(3): 371 - 375.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.